Ernexa Therapeutics Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
ERNA$2.05+9.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
| Three months ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating expenses: | ||
| Research and development | $1,915 | $1,309 |
| General and administrative | 1,631 | 1,421 |
| Impairment of goodwill | 2,044 | - |
| Total operating expenses | 5,590 | 2,730 |
| Loss from operations | (5,590) | (2,730) |
| Other income (expense), net: | ||
| Forward sales contract expense | - | (5,335) |
| Change in fair value of warrant liabilities | - | 1 |
| Interest income, net | 44 | 5 |
| Other expense, net | - | (135) |
| Total other income (expense), net | 44 | (5,464) |
| Loss before income taxes | (5,546) | (8,194) |
| Benefit (provision) for income taxes | 40 | (8) |
| Net loss | $(5,506) | $(8,202) |
| Net loss per common share - basic and diluted | $(6.95) | $(57.76) |
| Weighted average shares outstanding - basic and diluted | 792 | 142 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.